Lipid Nanoparticles with a Solid Matrix (SLN®, NLC®, LDC®) for Oral Drug Delivery

REFERENCES

• A. J. Almeida, S. Runge, and R. H. Müller. (1997). Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters. Int. J. Pharm. 149:255–265.
   Web of Science ®Google Scholar
• M. Armand, P. Borel, B. Pasquier, C. Dubois, M. Senft, M. Andre, and et al (1996). Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum. Am. J. Physiol. 271 (1 Pt 1):G172–G183.
   PubMed Web of Science ®Google Scholar
• R. Cavalli, O. Caputo, and M. R. Gasco. (1993). Solid lipospheres of Doxorubicin and Idarubicin. Int. J. Pharm. 89:R9–R12.
   Web of Science ®Google Scholar
• S. A. Charman, W. N. Charman, M. C. Rogge, T. D. Wilson, F. J. Dutko, and C. W. Pouton. (1992). Self-emulsifying drug delivery systems: Formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm. Res. 9 (1):87–93.
   PubMed Web of Science ®Google Scholar
• W. N. Charman. (2000). Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J. Pharm. Sci. 89 (8):967–978.
   PubMed Web of Science ®Google Scholar
• W. N. Charman, C. J. Porter, S. Mithani, and J. B. Dressman. (1997). Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J. Pharm. Sci. 86 (3):269–282.
   PubMed Web of Science ®Google Scholar
• W. N. Charman, and C. J. H. Porter. (1996). Lipophilic prodrugs designed for intestinal lymphatic transport. Adv. Drug Del. Rev. 19 (2):149–169.
   Web of Science ®Google Scholar
• A. Dingler, R. P. Blum, H. Niehus, R. H. Müller, and S. Gohla. (1999). Solid lipid nanoparticles (SLN/lipopearls)-a pharmaceutical and cosmetic carrier for the application of vitamin e in dermal products. J. Microencaps. 16 (6):751–767.
   PubMed Web of Science ®Google Scholar
• A. Dingler, G. Lukowski, S. Gohla, and R. H. Müller. (1997). Production and characterisation of solid lipid nanoparticles as colloidal carrier system for cosmetic products. Conference Proceeding, 2nd World Congress on Emulsion, Bordeaux
   Google Scholar
• C. Freitas. (1998). Feste lipid-nanopartikel (SLN): Mechanismen der physikalischen Destabilisierung und Stabilisierung. PhD thesis, Freie Universität, Berlin.
   Google Scholar
• C. Freitas, and R. H. Müller. (1998). Spray drying of solid lipid nanoparticles (SLNTM). Eur. J. Pharm. Biopharm. 46:145–151.
   PubMed Web of Science ®Google Scholar
• M. R. Gasco. (1993). Method for producing solid lipid microspheres having a narrow size distribution, U.S. Patent No. 5, 250, 236.
   Google Scholar
• R. Holm, C. J. Porter, A. Mullertz, H. G. Kristensen, and W. N. Charman. (2002). Structured triglyceride vehicles for oral delivery of halofantrine: Examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm. Res. 19 (9):1354–1361.
   PubMed Web of Science ®Google Scholar
• C. Keck, A. Fichtinger, H. Viernstein, and R. H. Müller. (2004). Oral drug nanocrystals – effect of potential aggregation on bioavailability, Abstract, American Association of Pharmaceutical Scientists Annual Meeting, Baltimore.
   Google Scholar
• C. M. Keck. (2006). Cyclosporine nanosuspensions: Optimised size characterisation & oral formulations. PhD thesis, Freie Universität Berlin, Berlin.
   Google Scholar
• S. M. Khoo, C. J. Porter, and W. N. Charman. (2000). The formulation of Halofantrine as either non-solubilizing PEG 6000 or solubilizing lipid based solid dispersions: Physical stability and absolute bioavailability assessment. Int. J. Pharm. 205 (1–2):65–78.
   PubMed Web of Science ®Google Scholar
• S. M. Khoo, D. M. Shackleford, C. J. Porter, G. A. Edwards, and W. N. Charman. (2003). Intestinal lymphatic transport of Halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs. Pharm. Res. 20 (9):1460–1465.
   PubMed Web of Science ®Google Scholar
• S. H. Klang, M. Parnas, and S. Benita. (1998). Emulsions as drug carriers – possibilities, limitations and future perspectives. In R. H. Müller, S. Benita, and B. H. L. Böhm. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs (pp. 31–60). Stuttgart: Medpharm Scientific Publishers.
   Google Scholar
• A. Kuksis. (1987). Absorption of fat soluble vitamins. In Fat absorptionA. Kuksis. Boca Raton: CRC Press. 265–86.
   Google Scholar
• A. Leviton, and M. J. Pallansch. (1959). Continuous recycling in the homogenization of relatively small samples. J. Dairy Sci. 42:20–27.
   Web of Science ®Google Scholar
• G. G. Liversidge, and P. Conzentino. (1995). Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125 (2):309–313.
   Web of Science ®Google Scholar
• G. G. Liversidge, and K. C. Cundy. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline Danazol in beagle dogs. Int. J. Pharm. 125 (1):91–97.
   Web of Science ®Google Scholar
• G. Lukowski, G. Hoell, A. Dingler, R. Kranold, and P. Pflegel. (1998). Drug localization in solid lipid nanoparticles. In Emulsions and nanosuspensions for the formulation of poorly soluble drugsR. H. Müller, S. Benita, and B. H. L. Böhm. Stuttgart: Medpharm Scientific Publishers. 341–344.
   Google Scholar
• G. Lukowski, G. Hoell, R. Kranold, R. Gehrke, and P. Pflegel. (1997). Fractal surface of solid lipid nanoparticles. Proceed. Int. Symp. Control. Rel. Bioact. Mater. 24:631–632.
   Google Scholar
• W. Martindale. (1989). The Extra Pharmacopoeia (29th ed., pp. 614–619). J. E. F. Reynolds. London: The Pharmaceutical Press.
   Google Scholar
• W. Mehnert, and K. Mäder. (2001). Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Del. Rev. 47 (2–3):165–196.
   PubMed Web of Science ®Google Scholar
• W. Mehnert, A zur Mühlen, A Dingler, H Weyhers, and R. H. Müller. (1997). Solid lipid nanoparticles (SLN) – ein neuartiger wirkstoff-carrier für kosmetika und pharmazeutika, II. Wirkstoffinkorporation, freisetzung und sterilisierbarkeit. Pharm. Ind. 59 (6):511–514.
   Google Scholar
• A. Meinzer, E. Müller, and J. Vonderscher. (1998). Perorale mikroemulsionsformulierung – sandimmun optoral/neoral. In Pharmazeutische technologie: moderne arzneiformenR. H. Müller, and G. E. Hildebrand. Stuttgart: Wissenschaftliche Verlagsgesellschaft. 2169–177.
   Google Scholar
• B. W. Müller. (1986). Suppositorien – pharmakologie, biopharmazie und galenik rektal und vaginal anzuwendender arzneiformenStuttgart: Wissenschaftliche Verlagsgesellschaft mbH.
   Google Scholar
• R. H. Müller. 1997. Zubereitung in Form eines wahlweise wirkstoffhaltigen Matrix-Hilfsstoff Compounds (Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance). U.S. Patent No. PCT/EP97/06893 (P 47025).
   Google Scholar
• R. H. Müller. 1996. Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN)/Medication vehicles made of solid lipid particles (solid lipid nanospheres – SLN). European Patent EP 0605497 B1.
   Google Scholar
• R. H. Müller, K. Mäder, A. Lippacher, and V. Jenning. (2000a). Fest-flüssige (halbfeste) Lipidpartikel und Verfahren zur Herstellung hochkonzentrierter Lipidpartikeldispersionen. PCT application PCT/EP00/04565.
   Google Scholar
• R. H. Müller, K. Mäder, and S. Gohla. (2000b). Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (1):161–177.
   PubMed Web of Science ®Google Scholar
• R. H. Müller, A. Dingler, T. Schneppe, and S. Gohla. (2000). Large scale production of solid lipid nanoparticles (SLNTM) and nanosuspensions (DissoCubesTM). In D. Wise. Handbook of pharmaceutical controlled release technology (pp. 359–376). New York: Marcel Dekker Inc.
   Google Scholar
• R. H. Müller, A. Dingler, H. Weyhers, A. zur Mühlen, and W. Mehnert. (1997a). Solid lipid nanoparticles (SLN) - ein neuartiger wirkstoff-carrier für kosmetika und pharmazeutika, III. Langzeitstabilität, gefrier- und sprühtrocknung, anwendung in kosmetika und pharmazeutika. Pharm. Ind. 59 (7):614–619.
   Google Scholar
• R. H. Müller, W. Mehnert, J. S. Lucks, C. Schwarz, A. zur Mühlen, H. Weyhers, and et al (1995). Solid lipid nanoparticles (SLN) – an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41 (1):62–69.
   Web of Science ®Google Scholar
• R. H. Müller, C. Schwarz, A. zur Mühlen, and W. Mehnert. (1994). Incorporation of lipophilic drugs and drug release profiles of Solid Lipid Nanoparticles (SLN). Int. Symp. Control. Release Bioact. Mater 2:1.
   Google Scholar
• R. H. Müller, C. Rimpler, R. Petersen, A. Hommoss, and K. Schwabe. (2007). A new dimension in cosmetic products by nanostructured lipid carriers (NLC) technology. Eur. Cosmet. 3:32–37.
   Google Scholar
• R. H. Müller, S. A. Runge, and V. Ravelli. 1998. Pharmaceutical cyclosporin formulation of improved biopharmaceutical performance and improved physical quality and stability and process for producing same. German Patent application DE 198 19 273 A1.
   Google Scholar
• R. H. Müller, S. Runge, V. Ravelli, W. Mehnert, A. F. Thünemann, and E. B. Souto. (2006). Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 317 (1):82–89.
   PubMed Web of Science ®Google Scholar
• R. H. Müller, S. A. Runge, V. Ravelli, A. F. Thünemann, W. Mehnert, and E. B. Souto. (2008). Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur. J. Pharm. Biopharm. 68 (3):535–544. Epub ahead of print July 17, 2007
   PubMed Web of Science ®Google Scholar
• R. H. Müller, H. Weyhers, A. zur Mühlen, A. Dingler, and W. Mehnert. (1997b). Solid lipid nanoparticles – ein neuartiger wirkstoff-carrier für kosmetika und pharmazeutika, I. Systemeigenschaften, herstellung und scaling-up. Pharm. Ind. 59 (5):423–427.
   Google Scholar
• R. H. Müller, S. A. Wissing, and A. Radomska. (2001). Clinical batch production of peptide-loaded nanoparticles. New. Drugs 1:72–74.
   Google Scholar
• C. Olbrich. (2002). Development of optimised lipid carriers and their investigation in biological systemsBerlin: PhD thesis, Freie Universität Berlin.
   Google Scholar
• C. Olbrich, A. Geßner, O. Kayser, and R. H. Müller. (2002a). Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug Diminazenediaceturate. J. Drug Targeting 10 (5):387–396.
   PubMed Web of Science ®Google Scholar
• C. Olbrich, O. Kayser, and R. H. Müller. (2002b). Lipase degradation of dynasan 114 and 116 solid lipid nanoparticles (SLN) – effect of surfactants, storage time and crystallinity. Int. J. Pharm. 237 (1–2):119–128.
   PubMed Web of Science ®Google Scholar
• C. Olbrich, W. Mehnert, and R. H. Müller. (1998). In vitro degradation properties of solid lipid nanoparticles SLN™. 2nd World Meeting on Pharmaceutics, BiopharmaceuticsPharmaceutical Technology. Paris.
   Google Scholar
• C. Olbrich, and R. H. Müller. (1999). Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int. J. Pharm., 180(1), 31–39.
   PubMed Web of Science ®Google Scholar
• J. S. Patton, and M. C. Carey. (1979). Watching fat digestion. Science 204 (4389):145–148.
   PubMed Web of Science ®Google Scholar
• L. Penkler, R. H. Müller, S. Runge, and V. Ravelli. (1999). Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. U.S. Patent No. PCT application PCT/EP99/02892.
   Google Scholar
• L. Penkler, R. H. Müller, S. Runge, and V. Ravelli. (2003). Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. U.S. Patent No. 6,551,619.
   Google Scholar
• J. F. Pinto, and R. H. Müller. (1996). Pellets as carriers of solid lipid nanoparticles (SLN) for oral administration of drugs. Eur. J. Pharm. Biopharm. 42:35S.
   Google Scholar
• C. J. Porter, S. A. Charman, A. J. Humberstone, and W. N. Charman. (1996). Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: Effect of lipid class and lipid vehicle dispersion. J. Pharm. Sci. 85 (4):357–361.
   PubMed Web of Science ®Google Scholar
• C. J. Porter, and W. N. Charmann. (2001a). Intestinal lymphatic drug transport: An update. Adv. Drug Deliv. Rev. 50 (1–2):61–80.
   PubMed Web of Science ®Google Scholar
• C. J. Porter, and W. N. Charmann. (2001b). Lipid-based formulations for oral administration: Opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J. Recept. Signal Transduct. Res. 21 (2–3):215–257.
   PubMed Web of Science ®Google Scholar
• C. W. Pouton. (2000). Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J. Pharm. Sci. 11 (2):S93–98.
   PubMed Web of Science ®Google Scholar
• M. Radtke. (2003). Grundlegende untersuchungen zur arzneistoffinkorporation, –freisetzung und struktur von SLN und NLCBerlin: PhD thesis, Freie Universität Berlin.
   Google Scholar
• S. A. Runge. (1998). Feste lipid-nanopartikel (SLN) als kolloidaler arzneistoffträger für cyclosporin ABerlin: PhD thesis, Freie Universität.
   Google Scholar
• C. Schwarz. (1995). Feste lipid nanopartikel: herstellung, charakterisierung, arzneistoffinkorporation und – freisetzungPhD thesis: Freie Universität, Berlin.
   Google Scholar
• D. M. Shackleford, W. A. Faassen, N. Houwing, H. Lass, G. A. Edwards, C. J. Porter, and et al (2003). Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. J. Pharmacol. Exp. Ther. 306 (3):925–933.
   PubMed Web of Science ®Google Scholar
• E. B. Souto, W. Mehnert, and R. H. Müller. (2006). Polymorphic behaviour of compritol 888 ATO as bulk lipid and as SLN and NLC. J. Microencapsul. 23 (4):417–433.
   PubMed Web of Science ®Google Scholar
• M. Stieß. (1995). Mechanische verfahrenstechnik 1Heidelberg: Springer Verlag.
   Google Scholar
• M. Stuchlik, and S. Zak. (2001). Lipid-based vehicle for oral drug delivery. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 145 (2):17–26.
   PubMedGoogle Scholar
• B. D. Tarr, and S. H. Yalkowsky. (1989). Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size. Pharm. Res. 6 (1):40–43.
   PubMed Web of Science ®Google Scholar
• K. Westesen, H. Bunjes, and M. H. J. Koch. (1997). Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Rel. 48:223–236.
   Web of Science ®Google Scholar
• A. zur Mühlen. (1996). Feste lipidnanopartikel mit prolongierter wirkstoffliberation: herstellung, langzeitstabilität, charakterisierung, freisetzungsverhalten und -mechanismenBerlin: PhD thesis, Freie Universität.
   Google Scholar
• A. zur Mühlen, and W. Mehnert. (1998). Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 53:552.
   Web of Science ®Google Scholar
• A. zur Mühlen, C. Schwarz, and W. Mehnert. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery – drug release and release mechanism. Eur. J. Pharm. Biopharm. 45:149–155.
   PubMed Web of Science ®Google Scholar
• A. zur Mühlen, C. Schwarz, W. Mehnert, and R. H. Müller. (1993). Produktion von ‘solid lipid nanoparticles’ (SLN) für die kontrollierte wirkstoffapplikation. Arch. Pharm. 326:752.
   Google Scholar